Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

OBJECTIVES: The aims were to demonstrate pharmacokinetic (PK) similarity between DRL_RI, a proposed rituximab biosimilar, and two reference innovator products (Rituxan(®) [RTX-US] and MabThera(®) [RTX-EU]) and compare their pharmacodynamics (PD), efficacy, safety, and immunogenicity in rheumatoid ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Haridas, Vikram Muralidhar, Katta, Rahul, Nalawade, Ajit, Kharkar, Sandeep, Zhdan, Vyacheslav, Garmish, Olena, Lopez-Lazaro, Luis, Batra, Sonica Sachdeva, Kankanwadi, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113224/
https://www.ncbi.nlm.nih.gov/pubmed/32052313
http://dx.doi.org/10.1007/s40259-020-00406-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113224/
https://www.ncbi.nlm.nih.gov/pubmed/32052313
http://dx.doi.org/10.1007/s40259-020-00406-1

Ejemplares similares